1. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma.
- Author
-
Kato R, Kojima T, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Sugino Y, Hamamoto S, Nakaigawa N, Kabu K, Murakami H, and Obara W
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Renal Cell mortality, Female, Humans, Ipilimumab pharmacology, Kidney Neoplasms mortality, Male, Middle Aged, Neoplasm Metastasis, Nivolumab pharmacology, Retrospective Studies, Survival Rate, Carcinoma, Renal Cell drug therapy, Ipilimumab therapeutic use, Kidney Neoplasms drug therapy, Nivolumab therapeutic use
- Abstract
Background/aim: To evaluate the effectiveness and safety of nivolumab plus ipilimumab for untreated metastatic renal cell carcinoma in real-world clinical practice in Japan based on 1-year follow-up results., Patients and Methods: This multicentre, retrospective study analysed 45 metastatic renal cell carcinoma patients who received nivolumab plus ipilimumab between August 2018 and January 2019 in Japan. Data were extracted from patients' medical records. Subgroup analyses were performed based on baseline demographic data and treatment history., Results: The objective response rate was 42.5% (complete response rate: 10.0%). The 12-month overall survival rate was 81.4% and the progression-free survival rate was 56.1%. Thirty-five patients (77.8%) showed any grade treatment-related adverse events and 17 (37.8%) showed grade ≥3 treatment-related adverse events, with no significant difference in safety between subgroups., Conclusion: The effectiveness and safety of nivolumab plus ipilimumab in real-world clinical practice with 1-year follow-up were comparable with those of the CheckMate 214 trial., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF